The Drug Supply Stops Being Just Fentanyl

What the May 12 DEA advisory actually says

On May 12, 2026, the Drug Enforcement Administration issued a Public Safety Advisory describing what its forensic labs are now consistently seeing in seized samples: fentanyl mixed with one or more potent additives. The two categories the agency named are veterinary sedatives (xylazine and, increasingly, medetomidine) and a new generation of synthetic opioids (nitazenes and cychlorphine).

The numbers in the advisory are worth pausing on. DEA has identified 22 distinct nitazene compounds in U.S. samples since 2020. Twenty-one of them are now Schedule I. Medetomidine — colloquially “rhino tranq” — is, by DEA’s own estimate, 200 to 300 times more potent than xylazine. Cychlorphine, an “orphine” synthesized in old pharmaceutical literature and never approved for clinical use, has now been confirmed in 22 forensic samples across at least eight states: Tennessee, Illinois, Ohio, Oklahoma, California, South Carolina, Kentucky, and Georgia.

This is what the editor of every harm-reduction newsletter we read has been saying for the last six months: “the supply is changing, fast.” The DEA advisory is the federal version of that statement.

The biology — and why naloxone is necessary but not sufficient

The thing that has shifted is the mix.

Naloxone reverses opioid overdoses by displacing opioids from mu-opioid receptors. It works on fentanyl. It works on heroin. It works on nitazenes and cychlorphine — these are still opioids, just newer and unfamiliar ones, and the existing dose math (start at 4mg intranasal; redose if no response in 2–3 minutes) holds, though several doses may be needed.

Naloxone does not work on xylazine. It does not work on medetomidine. These are alpha-2 agonists; they cause sedation, slowed breathing, and bradycardia through an entirely different receptor pathway. When someone overdoses on a fentanyl–medetomidine mix, naloxone can restore the opioid-driven portion of the respiratory depression — that is the difference between life and death — but the sedation can persist, the breathing can stay shallow, and the person can need extended supportive care that goes well past the naloxone window.

This is the science behind the advisory’s most important line: “naloxone may not fully reverse the effects.” It does not mean naloxone has stopped working. It means the public-facing instructions for what to do after naloxone is given are no longer optional. Stay on scene. Call 911. Keep the airway open. Be prepared for the person to be sedated longer than the naloxone reversal would predict.

What this changes for families and first responders

A growing share of overdose reversals — particularly in rural areas and outside of major cities — are now performed by family members, not by EMS or harm-reduction staff. The CDC’s own conversation-starter guidance for caregivers was updated this spring to reflect this.

The implication: the script families learned three years ago — “give naloxone, wait, give a second dose if needed, person wakes up, you’re done” — is no longer the script. It is closer to: “give naloxone, immediately call 911, expect that even if breathing returns the person may not fully wake, stay until help arrives.” That is a meaningfully harder ask, especially in households where the family member calling is also navigating fear of arrest for the person they just rescued.

This is the part of the conversation that is least loud right now and that, in our reading, matters most. Caregiver overdose response is becoming the front line. The training that’s available has not fully caught up.

Where the field disagrees

There is genuine disagreement about how alarmed to be. Filter Magazine has argued that “more deadly than fentanyl” framing around nitazenes is misleading and risks fueling drug-war narratives. The DEA’s framing leans more toward immediate threat. Both can be true at once: the biology is genuinely more complex than a single-opioid supply, and the response infrastructure (naloxone access, overdose-response training, harm-reduction outreach) is the same set of tools that has been bending the national overdose curve. The fight is over whether to lead with the warning or with the proven response.

The fight is over whether to lead with the warning or with the proven response.

We lean toward the response. Naloxone still works on the opioid component. Test strips are still the first line of defense against an unfamiliar mix. Calling 911 is still the right thing to do. The supply being more complex makes those three actions more important, not less.

Resources

• Free naloxone, anywhere in Arizona, no questions asked: Shot in the Dark.
• Caregiver overdose conversation guide: CDC.
• We are building Rize’s Naloxone & Harm Reduction Hub to surface distribution points and updated response training, with a planned Family & Caregiver Portal for the people who increasingly carry this work.

If you or someone you love is in crisis, call or text 988.